San Diego-based Viking Therapeutics marked itself as a significant competitor within the weight loss drug current market in February just after revealing promising facts from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection and in March the company